Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
AMBS is Moving MANF imminently closer to a first-in-man study for one or more indications where there is relatively little competition, and where MANF has the potential to have significant disease-modifying effects in these multi-billion dollar market opportunities
http://www.thechairmansblog.com/gerald-commissiong/2013-05/continued-progress-with-our-business-plan-in-central-nervous-system-disorders.html
The upcoming activities related to Amarantus’ Parkinson’s disease program include:
Create mammalian GMP production processes for MANF; the Company has sourced the expertise for these activities, and has started development of the supporting analytical and bioanalytical assays;
Form a partnership agreement in the third quarter of 2013 with a firm specializing in Convection-enhanced delivery (CED) of drugs to the brain;
Initiate non-human primate pharmacology studies in Parkinson's disease models in the second half of 2013 in order to establish an appropriate dosing regimen for human clinical studies;
Potentially evaluate MANF gene therapy based upon upcoming developments in the field of neurotrophic factors for Parkinson’s disease, and the Company’s current patent position whereby the Company owns exclusive rights to MANF gene therapy applications in all vector systems.
Additional planned activities are expected to include:
Conduct pharmacokinetic and pharmacodynamic (PK/PD) studies, with data available in the third quarter of 2013, to evaluate the biological properties of MANF when administered systemically, with data to be released as it becomes available;
Conduct pharmacology studies in traumatic brain injury, ischemic heart disease, diabetes and certain other animal models in the third quarter of 2013, with data to be released as it becomes available;
Evaluate MANF in a variety of animal models of orphan diseases in the third quarter of 2013 that represent significant market opportunities, and where there is limited or very limited competition;
Initiate MANF toxicology studies upon development of a master cell bank of MANF protein material as one of the final pre-IND steps;
File an IND in 2014.
“Based on our progress with these preclinical activities and the interest and level of data in specific indications, we will seek to partner with biopharmaceutical companies or appropriate not-for-profit disease foundations in order to accelerate our development program and assist in recruiting patients for future clinical studies,” said Mr. Commissiong. “We will prioritize our clinical development programs based upon the outcome of the pharmacology studies that will begin in the third quarter of 2013 for the indications outlined here today. We intend to give highest priority to those indications where we have a shorter path to market, and where non-dilutive financing is available to support further development. Fortunately for the Company, it is likely that many of the pre-clinical studies will have applications across indications, meaning we will get the advantage of a particular set of data enabling multiple indications.”
The Company will seek to gain ‘Breakthrough,’ ‘Fast Track’ and/or ‘Orphan Drug Designation’ status with the FDA where the Company believes the data generated justifies such a designation, potentially significantly reducing the time to market for MANF and/or improving the potential economic outcome for the Company.
The Company believes MANF could address the following very significant market opportunities:
Parkinson’s disease: $1 billion
Traumatic Brain Injury: $200 million
Ischemic Heart Disease: $2 billion
Diabetes: $2 billion
Orphan diseases: $2 billion
http://ir.stockpr.com/amarantus/company-news/detail/674/amarantus-announces-preclinical-development-timeline-for-manf-therapeutic
$AMBS & $BD* - Dr. Simon is on the Board to make this happen, and soon the AMBS Diagnostics division will fuel the rest of AMBS Holdings.
And MJFF is not done with MANF , you will see When MANF is paired with a L-Dopa Drug Candidate that has already been funded by MJFF...
IND's = $$$$
Orphan IND's = More $$$$$$$$$$
I have the luxury to be patient here, I was in the 1st run of AMBS and I made a nice chunk...
if you are in a hurry go sign up for some newsletters via email..
GL2ALL
$AMBS Board of Advisors -
Dr. Joseph Rubinfeld
Corporate Advisor
Dr. Rubinfeld is one of the four original co-founders of Amgen. Dr. Rubinfeld co-founded Amgen after a 23 year career in a variety of senior scientific and operational positions at Bristol Myers Squibb. Dr. Rubinfeld served as a Senior Director at Cetus Corporation from 1987 to 1990 until co-founded SuperGen in 1991, and served as its President & CEO through 2003. Dr. Rubinfeld is credited with inventing Amoxicillin, biodegradeable detergent and polaroid film. Dr. Rubinfeld received his PhD in Chemistry from Columbia University.
Dr. Adam J. Simon
Corporate Advisor
Dr. Simon is the founder and president of AJ Simon Enterprises, LLC, a consulting firm serving pharmaceutical and biotechnology clients, including Bristol Myers Squibb. He is also the founder and chief executive officer of Cerora, Inc., a healthcare information technology company focused on developing medical devices and services to assess brain health, including Traumatic Brain Injury. Earlier in his career he spent more than 13 years at Merck Research Laboratories, where he served as a Senior Research Fellow in Integrative Systems Neuroscience and Biomarkers and in Alzheimer’s disease research. He has also been a visiting scientist at Princeton University. Dr. Simon received Bachelor’s degrees in Physics and Mathematics from the University of Rochester. He received a Doctorate in Physics from the University of Chicago. He holds four patents related to medical research, and has published more than 60 articles in scientific and medical journals.
Dr. Robert J. Zimmerman
Product Development Advisor
Dr. Zimmerman is currently a biopharmaceutical product development consultant in the Bay Area at Zimmerman Consulting. Prior to starting his company, Dr. Zimmerman held senior management positions at Signature BioScience, Inc. where he served as Chief Operating Officer and as President, overseeing all research and development activities. Previously, he served as Vice President of Biotechnology Research at Bayer Corporation, where he was responsible for the management of all biotechnology research activities within the Pharmaceutical Division. At Bayer, he managed five departments including molecular technologies, scientific informatics, cell and analytical biology, pharmacology and preclinical development. Prior to Bayer, he served in positions of increasing responsibility at Chiron Corporation. Dr. Zimmerman has been involved in the submission of dozens of Investigational New Drug applications to the U.S. Food & Drug Administration and other regulatory agencies in a variety of indications, as well as successful marketing applications including interleukin-2 (IL2) and beta-interferon. Dr. Zimmerman received a doctor of science degree in physiology and radiobiology from the Harvard School of Public Health. He also earned a M.S. in physiology from The Ohio State University and a B.S. from Denison University.
Dr. Owen Garrick
Corporate Advisor
Dr. Garrick joins Amarantus with over 20 years of pharmaceutical and biotechnology experience. He currently serves as the Chief Operating Officer at Bridge Clinical Research and is President of the American Medical Association Foundation. Prior to that, he was Director of Corporate Strategy and Business Development at McKesson Corporation. Dr. Garrick was Executive Director and Co-Head of Mergers & Acquisitions at Novartis Pharmaceuticals where he oversaw company acquisitions, hybrid equity/license rights deals, mature product divestments and venture investments in biotechnology companies. Prior to Novartis, Dr. Garrick was an associate at Goldman Sachs in New York. Dr. Garrick received his MD from Yale School of Medicine and earned his MBA from Wharton School of Business. He holds an AB from Princeton University, where he has served on the national fund raising board.
Mr. Toi Cook
Corporate Advisor
Mr. Cook had an 11 year career in the NFL, playing for the New Orleans Saints, San Francisco 49ers and Carolina Panthers. Mr. Cook had an interception as a defensive back in the 1994Super Bowl championship for the San Francisco 49ers. Since retiring from the NFL, Mr. Cook has worked primarily in Sports and Entertainment. He was Executive Vice President in the Sports Division at the Gersh Agency in Los Angeles from 2004-2006. He is the principle at Toi Cook Management Group, LLC (TCMG), which has consulted for Broadband Sports, A2A Holdings and Dreier Sports. He is currently a plaintiff in a lawsuit of former NFL players against the NFL in relationship to concussions sustained while playing. He served as the Player Representative for the NFLPA for eight years when he was a player in the NFL. He was a football and baseball star at Stanford University, where he graduated in Communications after winning the College World Series in 1987.
nice treatment alternative of symptoms for those in need... but as you know AMBS & MANF is more along the lines of a disease modifying drug candidate.
I would hardly trust anyone's judgement on AMBS when they have the math and accounting skills that do not know the difference between a 180 & a 360 ....
#LymPro market potential high end is 500 Million per.. and once the already paid for GLP Lab verifies the results that the blood test has already turned out before......that same LAB/ and then New JV partner will pay for taking #LymPro to market , all AMBS will have to do is collect a nice upfront cash payment and the monthly residual royalties on sales in the future... and this is not counting the other new idea's they have to expand what LYMPRO can test for TBI, PD, ect ect ....
PS. When have you been to Gerald's House to know his living habits?
$AMBS ---- #LymPro ---- Alzheimer's is a disease that can last a really long time and cost a lot of money — so much money, in fact, that the U.S. government is paying attention with new legislation.
In 2011, Obama signed the National Alzheimer's Project Act into law. Currently, about $500 million per year goes to Alzheimer's research, and the new law includes an additional $100 million toward treatment, research, medicine and diagnostic tools.
http://www.npr.org/2013/05/18/185103746/alzheimers-cases-rise-but-hope-remains
Billion Dollar drug candidate days away from starting Human clinical trials for BMSN. Nice try though
LymPro was licensed from Memory DX , get the facts straight..nothing to do with Power3
Once BD validates the data.. you will be once again kicking yourself for losing out $$$$$$$$$$$$$$$$
Money Makes Money $$$$$$$
$$$$$$$$
$$$$$$
$$$$$
$$$$
$$$
$$
$AMBS
thanks for the info,,, just read comments talking of possible EPGL Dilution and I see that big number staring at me.. keep fingers crossed for after December..
WOW 5 Billion AUTHORIZED 4.7B O/S for EPGL and they are going to dilute again? what are they going to increase A/S?
company looks promising but this share structure will be hard to move... may buy some here but I will wait til I am certain they don't increase O/S
GL2ALL
Very simple once BD confirms data previously produced for LymPro. The JV with AMBS will be announced to bring it to market. Stay out of you like or buy it cheaper. But you will be buying it. GL2ALL
BD + AMBS. - just like i called.
--------////////
You have never seen the movie Godfather?
AMBS will provide the answers to all our questions.
Once WEST obtains certificate of conformity for US and Auzzie Markets for CBD to produce their patented solar panels. , merger will be completed and we will be off to the races.
GL2ALL
AMBS - a lot will be revealed soon enough....
where our MANF asset with multiple product development opportunities is slated to be aligned with a clinical-stage therapeutic asset primed to move into mid-stage development. Once achieved, we expect Amarantus to be positioned to move much closer towards our stated objective of up-listing to a national stock exchange.
Speak for your self. I made big profit on BMSN 1st run to .015 now back for next run . You just bought at wrong time. This is all. GL next time.
78% of Orphan IND 's are approved. BMSN is that much closer. $$$$$$
AMBS rumored LymPro development partner BD - Becton Dickinson Diagnostics
About BDBD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs nearly 30,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.
Once IND for Orphan indication is approved which it will be, due to the need in the market. BMSN will be in the nickels and dime area. And then the buyout rumors really pump us.
$$$$$$$$& hold for gold BMSN
BMSN has more IND's on the way= more shareholder value. $$$$$$$
10M and buying.
78% of Orphan IND's are approved. BMSN has the right drug at the right time. $$$$$$$$$
I do break TOS but more egregious offenders are still allowed to post unwarned or penalized.. ... and i do see the same things you mention on the board I frequent
Not valid point because the Lympro test they acquired the license from Memory Dx. And that has nothing to do with tests they bought from Power3.
Lympro is the near term catalyst. With $500 Million per year potential and this is coming from one of the Top world renowned experts in Alzheimer's Biomarkers. Dr. Simon who now is on the board of AMBS for the purpose of guiding this test to market.
GL2UALL
if you bought when I told you. you would already be up Money on AMBS
you should take advice when you ask for it.
GL2U
Thanks for update, the Best deals are made on Golf courses. AMBS.
AMBS has an approach to help PD patients. Not smart to use your theory of alpha-syn that has shown to make it worse. Its like hitting your head with a hammer to cure a headache.
Alpha-synclein approach makes PD worse
setBACK and a major one.. if the approach you were saying is a must, makes PD patients worse... yeah I'd say this is another plus for AMBS
wow your opinion has been blown to pieces.. NEXT
alpha-synuclein approach does not work, makes PD worse . One of the most promising new approaches to treating Parkinson’s disease hit a snag after researchers found early evidence it may make people worse.
The experimental technique involves reducing levels of alpha-synuclein, a protein found in clumps in the brains of people with Parkinson’s that increases the risk of the disease. Research presented at the American Academy of Neurology meeting in San Diego shows the condition progresses more rapidly in patients with naturally low levels of the protein.
No need to deny what you know is not the answer, AMBS is on correct path.
http://mobile.bloomberg.com/news/2013-03-21/parkinson-s-patients-may-be-harmed-by-novel-treatment.html
No FDA validation needed, due to no surgery for cure.
Diagnostics are going to Phase 2 no approval needed, then CLIA certification is what is needed. Commercialization of the diagnostics will begin this year. Revenue can begin as RUO & CDx
Wrong again on MJFF and AMBS
AMBS GLP partner is a Multi Billion Dollar company = instant credibility
Their PD drug is for symptoms not disease modifying like MANF's potential and FDA thinks it increases prostate cancer
10 bagger here. NNAN. Thats what my selling point is.
GL2ALL
NNAN next run will be like AMB% ...... rocket to Silver land... ZIP Code Changer....
GL2ALL
Turn chart upside down , you are looking at it wrong. BMSN set to go up. GL 2 u and your belt
Definitely. NNAN ready to run. Chart is set